A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease
説明
<jats:p>The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer’s disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6–12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.</jats:p>
収録刊行物
-
- European Neurology
-
European Neurology 44 (4), 236-241, 2000
S. Karger AG
